August 11, 2017 08:11 AM EDT

GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts

John Carroll

Editor & Founder

Just three months after Ionis spelled out positive Phase III efficacy data on its top prospect inotersen, GlaxoSmithKline is sweeping their alliance on the drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

GSK aban­dons Ion­is' FDA-ready in­ot­ersen as new CEO sweeps out rare dis­ease ef­forts

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

GSK abandons Ionis' FDA-ready inotersen as new CEO sweeps out rare disease efforts

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration